Full Press Release Details
Immutep Quarterly Activities Report Q3 FY24.
IMMP
Immutep Quarterly Activities Report Q3 FY24
Key Takeaway: Immutep Quarterly Activities Report Q3 FY24
Price reaction · baseline $2.65 (2024-04-26 close) · 2 other IMMP headline(s) in the window, move may be shared
day 0 close
+0.8%
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+76%
120-day peak, hindsight
Typical move
5.4%
average across 13 past catalysts
Lead asset
eftilagimod alfa
Phase 3 · Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)